Cargando…
Benralizumab: a unique IL-5 inhibitor for severe asthma
The presence of eosinophilic inflammation is a characteristic feature of chronic and acute inflammation in asthma. An estimated 5%–10% of the 300 million people worldwide who suffer from asthma have a severe form. Patients with eosinophilic airway inflammation represent approximately 40%–60% of this...
Autores principales: | Tan, Laren D, Bratt, Jennifer M, Godor, Dorottya, Louie, Samuel, Kenyon, Nicholas J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4831605/ https://www.ncbi.nlm.nih.gov/pubmed/27110133 http://dx.doi.org/10.2147/JAA.S78049 |
Ejemplares similares
-
Self-Administered Mepolizumab in the Management of Severe Asthma: Usability and Patient Acceptance
por: Miyokawa, Reika, et al.
Publicado: (2020) -
The clinical profile of benralizumab in the management of severe
eosinophilic asthma
por: Menzella, Francesco, et al.
Publicado: (2016) -
Childhood-onset severe hypereosinophilic asthma: efficacy of benralizumab
por: Just, Jocelyne, et al.
Publicado: (2020) -
Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma
por: Noorduyn, Stephen G., et al.
Publicado: (2021) -
Effectiveness of Switching to Benralizumab in Severe Refractory Eosinophilic Asthma
por: Gómez-Bastero Fernández, Ana, et al.
Publicado: (2022)